The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. - sprookjes - yvandenbroek - TriplyDB

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

http://www.wikidata.org/entity/Q33834958

about

KASL clinical practice guidelines: management of hepatitis C Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis Emerging therapies for the treatment of hepatitis C Best strategies for global HCV eradication.Hepatitis C screening Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.Hepatitis C virus screening in patients with cancer receiving chemotherapy.Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda.Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?Ending hepatitis C in the United States: the role of screening.Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs Current and future disease progression of the chronic HCV population in the United States.Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.Cost-effectiveness of screening for hepatitis C in Canada.HCV and HIV co-infection: mechanisms and management.The changing burden of hepatitis C virus infection in the United States: model-based predictions.Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program Cost-effectiveness and population outcomes of general population screening for hepatitis C.A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: a cross-sectional study.Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care.The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma.Hepatitis C screening: getting it right.An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.Age-period-cohort analysis of infectious disease mortality in urban-rural China, 1990-2010."Know More Hepatitis:" CDC's National Education Campaign to Increase Hepatitis C Testing Among People Born Between 1945 and 1965

P2860

Q26752471-A35690E8-4718-46A4-BF10-4F90BD9F2B46 Q26774500-088906EE-C790-4669-BE0D-8D0EA00F1427 Q26777560-EC556417-21F0-4B75-A796-CF932D1EA01A Q27003319-76FD5C9E-78D5-4E40-A1F8-6CBB685B6F25 Q27693824-A01AF63C-BB55-4724-BC02-79C8E4618095 Q28083429-EA28728B-83A1-40D3-8EF9-8912A01F900C Q28488762-304FC756-71EE-47CA-BBB8-CD5DDE74BE36 Q28545237-64AE81AE-31F1-4DB9-97D4-B18273572D55 Q28681550-35990239-D79B-498F-9143-9DB128F595FD Q30235430-17411794-3ACB-4890-B67C-7F386FF077CC Q33590896-E14ADF1A-AA7A-4BDC-A804-464FB5E220B9 Q33600085-49F69E4E-0154-4159-BFC1-E2DDD143FB73 Q33630346-4C968502-00D1-4AE9-A40D-16EA78A626FB Q33810973-44EB1DEE-8E12-4FFD-BE3F-21B112C7E905 Q33837518-8B8563B5-A0A4-4A92-A65B-F84BCA3DBE67 Q33858322-29D22BF1-FE9C-4664-A1D9-B20533CCF529 Q33862919-67927766-0985-4BC6-8F88-027B463B89AE Q34510773-51589B04-0364-4712-B862-E78C0D50FBDD Q34524584-54F56E57-8F54-4BEB-A53F-0714919C729D Q34609276-08B2C5B2-25F1-4931-A081-82132350386D Q34677180-2EBA524B-C791-4800-BE35-6594596112BA Q34735072-18507A67-563C-4514-B0F7-CB7A49A93047 Q34737843-211D4A87-953F-4E44-9BF4-D70CDC85E361 Q35058571-A842CDF2-9226-42BA-8458-E3C2FA81CE6A Q35088460-9938EFB9-42E7-4D4D-9027-03CE9D29F6CD Q35090634-AFF944A3-4617-4E5E-8DC6-A619B538222C Q35168083-31B0C276-1CA9-48AB-AD9F-F956030A611F Q35197198-CAAC847A-88B9-44DD-A05F-4B06A7842954 Q35241062-841C06CF-5EC7-452C-BE47-57E85418C1BF Q35619161-3ABBA03B-AF8C-46AA-922D-96CD5DF547B6 Q35752660-D71B3D06-4457-41D4-8639-23E0CF8B6D8E Q36115516-414F1628-0BF6-4132-B413-98BDB012A7AA Q36340733-744DBA7F-5FEC-461A-9CCD-5FDD1B1B3421 Q36425701-808FD654-EF21-43FA-A54A-9A79D9C4CEAA Q36446133-D13931F4-E863-4455-9163-27803A3B0D94 Q36456976-4DBD67AB-73AD-4976-A171-7937F53F129D Q36575211-57CB2148-DB89-421E-B904-19841F1D30D2 Q36590778-72CB65BF-6C31-4C33-ABA8-F1788D3F676B Q36748876-85A9B3A2-18CB-497A-9ED5-02726703763E Q36858849-BCADDB89-E479-4803-87F2-EACECA5C5AC8

P2860

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

http://www.wikidata.org/entity/Q33834958

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The cost-effectiveness of birt ...... in U.S. primary care settings.

@ast

The cost-effectiveness of birt ...... in U.S. primary care settings.

@en

type

label

The cost-effectiveness of birt ...... in U.S. primary care settings.

@ast

The cost-effectiveness of birt ...... in U.S. primary care settings.

@en

prefLabel

The cost-effectiveness of birt ...... in U.S. primary care settings.

@ast

The cost-effectiveness of birt ...... in U.S. primary care settings.

@en

P1433

Q33834958-B58EB45A-C0E9-42D6-807E-57A18A2A4C1E

P1476

Q33834958-509AF52C-5869-4EC2-9393-035AB4556643

P2093

Q33834958-265CC267-EA30-4AA9-84ED-7226CC26D70C

Q33834958-6E80D7A5-0245-4F10-BF76-7D1B9C14D684

Q33834958-7BA433B4-0C66-46BF-B6A4-E9432E5C30FC

Q33834958-BC7D3174-D39D-4B4B-B210-5F61A797A699

Q33834958-CBAB054F-56C1-401B-9304-0321ACC05984

Q33834958-D91CD981-02D1-4C70-9D0F-C113252F94C4

Q33834958-E61B46F0-D566-4EA1-9FBB-510031847FEC

Q33834958-EE8C52EC-4FF0-4B5D-817D-0C8D7266249F

Q33834958-F87B8748-8AEB-4F62-AA1D-161FFA71E76A

P2860

Q33834958-00CA9759-DABB-45EC-8002-7B45BA257DC4

Q33834958-06558B18-B103-4B17-8A91-4E6FB0EB334E

Q33834958-0FCDE301-F0F9-4FEC-BEC2-1810D9ADDF10

Q33834958-1541ED5C-7B19-44A0-8632-A85CC79EF965

Q33834958-172D7FCC-4609-4F53-A071-332B7FA684FC

Q33834958-17953A46-FB11-4B9A-8ED9-14A750FC6A02

Q33834958-23A4051E-5F7D-4554-AFB0-56ACB77D3299

Q33834958-23D7A597-A26D-46A2-BCEE-D1A754717D50

Q33834958-2D2E62BD-3B92-4C12-BA8C-50C2E2A4834A

Q33834958-2D35257D-D50A-4D11-B30D-180A38166C55

P304

Q33834958-99EC9B0E-FAC9-4BB6-A405-2EC809377D27

P31

Q33834958-E8C4216C-9B60-4E2D-B4D2-B21EA6F2F31E

P356

Q33834958-1169B1EC-D4A3-4775-913F-ECFE191733AA

P407

Q33834958-C22C2D53-D49C-4EC0-A06E-6D48BAE7C80B

P433

Q33834958-38774FFC-C501-4280-B723-312F8057F07D

P478

Q33834958-A7819EAA-1AC9-4EBD-8C44-019999502FE0

P577

Q33834958-96C7B64D-9663-470C-9181-0D3695D234A4

P698

Q33834958-07FBA077-B0DB-40A3-8A89-E8A303E14D19

P921

Q33834958-7705CCEC-00B9-4FC8-A4D7-EE997AB82852

Q33834958-FE818769-78C3-4B9C-9C51-A8234B34CABF

P932

Q33834958-65D5DD0B-43CA-4DBC-BDF7-E9A617B2ABEE

P356

0003-4819-156-4-201202210-00378

P1433

Annals of Internal Medicine

P1476

The cost-effectiveness of birt ...... in U.S. primary care settings.

@en

P2093

Bryce D Smith

http://www.w3.org/2001/XMLSchema#string

Cindy M Weinbaum

http://www.w3.org/2001/XMLSchema#string

David B Rein

http://www.w3.org/2001/XMLSchema#string

Douglas W Roblin

http://www.w3.org/2001/XMLSchema#string

John S Wittenborn

http://www.w3.org/2001/XMLSchema#string

John W Ward

http://www.w3.org/2001/XMLSchema#string

Laura D Wagner

http://www.w3.org/2001/XMLSchema#string

Nita Patel

http://www.w3.org/2001/XMLSchema#string

Sarah B Lesesne

http://www.w3.org/2001/XMLSchema#string

P2860

Self-reported hepatitis C virus antibody status and risk behavior in young injectors

Priorities among effective clinical preventive services: results of a systematic review and analysis

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

Telaprevir for previously untreated chronic hepatitis C virus infection

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Diagnosis, management, and treatment of hepatitis C

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.

Empirically calibrated model of hepatitis C virus infection in the United States.

P304

263-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-156-4-201202210-00378

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22056542

http://www.w3.org/2001/XMLSchema#string

P921

P932

5484577

http://www.w3.org/2001/XMLSchema#string